[2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients].

The <<Standards, Options : Recommendations>> (SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events (VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies ("société nationale française de médicine interne": SNFMI, "société française de médicine vasculaire": SFMV and "société française d'anesthésie-réanimation": SFAR).

[1]  Sonal Singh,et al.  Thromboprophylaxis in cancer patients with central venous catheters , 2007, Thrombosis and Haemostasis.

[2]  P. Wells,et al.  Thromboprophylaxis for catheter‐related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials , 2007, Journal of thrombosis and haemostasis : JTH.

[3]  G. Raskob,et al.  Prevention of central venous catheter-associated thrombosis: a meta-analysis. , 2007, The American journal of medicine.

[4]  C. Newburn-Cook,et al.  The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: a meta-analysis. , 2007, Oncology nursing forum.

[5]  H. Büller,et al.  Prevention of catheter‐related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo‐controlled study , 2007, Journal of thrombosis and haemostasis : JTH.

[6]  D. Cook,et al.  Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. , 2007, The Cochrane database of systematic reviews.

[7]  Russell D Hull,et al.  Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. , 2006, The American journal of medicine.

[8]  M. Mandalà,et al.  Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? , 2006, Chest.

[9]  Jawed Fareed,et al.  Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period , 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[10]  F. Wesenberg,et al.  Low‐dose warfarin for the prevention of central line‐associated thromboses in children with malignancies—a randomized, controlled study , 2006, Acta paediatrica.

[11]  U. Waheed,et al.  Inferior Vena Cava Filter Placement in Late-Stage Cancer , 2006, Vascular and endovascular surgery.

[12]  M. De Cicco,et al.  Short-term acenocumarine (A) or dalteparine (D) for the prevention of central venous catheter-related thrombosis (CVCrT) in cancer patients. A randomized controlled study based on serial venographies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Levine,et al.  Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Finlay,et al.  Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study , 2006, BMJ : British Medical Journal.

[15]  G. Steger,et al.  Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  B. White,et al.  Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence , 2006, British Journal of Cancer.

[17]  L. Castagna,et al.  High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Zerati,et al.  Vena cava filters in cancer patients: experience with 50 patients. , 2005, Clinics.

[19]  S. Laporte,et al.  Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. , 2005, Chest.

[20]  D. Anderson,et al.  Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Armando Santoro,et al.  Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Kerr,et al.  WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs) , 2005 .

[23]  B. Asselain,et al.  Thrombose symptomatique sur cathéter veineux central de longue durée en oncologie : un score de risque prédictif? , 2005 .

[24]  I. Finlay,et al.  Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study , 2005, Palliative medicine.

[25]  M. Prins,et al.  Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Vincent Vinh-Hung,et al.  Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports , 2005, Supportive Care in Cancer.

[27]  J. Kuhn,et al.  A prospective randomized trial demonstrating valved implantable ports have fewer complications and lower overall cost than nonvalved implantable ports. , 2004, American journal of surgery.

[28]  K. Ahrar,et al.  Use of inferior vena caval filters and survival in patients with malignancy , 2004, Cancer.

[29]  Clifford W Colwell,et al.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[30]  T. Ben Othman,et al.  Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease , 2004, Thrombosis and Haemostasis.

[31]  A. Maubon,et al.  Thrombotic complications of implanted central venous access devices: prospective evaluation. , 2004, Bulletin du cancer.

[32]  J. Eikelboom,et al.  Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. , 2004, Annals of internal medicine.

[33]  A. D. Van den Abbeele,et al.  The Treatment and Outcome of Cancer Patients with Thromboses on Central Venous Catheters , 2000, Journal of Thrombosis and Thrombolysis.

[34]  R. Sundaram,et al.  To clot or not to clot? That is the question in central venous catheters. , 2004, Clinical radiology.

[35]  Susanne M. Smorenburg,et al.  Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. , 2003, Archives of internal medicine.

[36]  A. Iorio,et al.  Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants , 2003, Journal of thrombosis and haemostasis : JTH.

[37]  L. Castagna,et al.  Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen. , 2003, Annals of Oncology.

[38]  A. Santoro,et al.  Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. Feder,et al.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project , 2003, Quality & safety in health care.

[40]  S. Laporte,et al.  Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. , 2003, Haematologica.

[41]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[42]  K. Calligaro,et al.  Inferior vena cava filters in malignant disease. , 2002, Journal of vascular surgery.

[43]  J. Dichgans,et al.  Low molecular weight heparin for deep vein thrombosis in glioma patients , 2002, Journal of Neurology.

[44]  N. Vučić,et al.  Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study. , 2002, Croatian medical journal.

[45]  D. Heaton,et al.  Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis , 2002, Internal medicine journal.

[46]  P. Vardas,et al.  PROPHYLAXIS WITH UROKINASE IN PEDIATRIC ONCOLOGY PATIENTS WITH CENTRAL VENOUS CATHETERS , 2002, Pediatric hematology and oncology.

[47]  Yves Gruel,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of internal medicine.

[48]  A. Luciani,et al.  Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. , 2002, Radiology.

[49]  F. Orsi,et al.  A randomized, prospective trial of central venous ports connected to standard open‐ended or Groshong catheters in adult oncology patients , 2001, Cancer.

[50]  A. Kakkar,et al.  Thromboembolism in brain tumors , 2001, Current opinion in pulmonary medicine.

[51]  J. Renaud-salis,et al.  SOR: project methodology , 2001, British Journal of Cancer.

[52]  J. Hirsh,et al.  A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy , 2000, Thrombosis and Haemostasis.

[53]  D. Wallace,et al.  Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. , 2000, American journal of clinical oncology.

[54]  J. Douketis,et al.  A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. , 2000, Archives of internal medicine.

[55]  M. Martínez-González,et al.  Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. , 2000, Haematologica.

[56]  K. Savage,et al.  Outpatient Use of Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity , 1999, Thrombosis and Haemostasis.

[57]  R. Bona,et al.  Regional Thrombolysis with Urokinase for Central Venous Catheter-related Thrombosis in Patients Undergoing High-dose Chemotherapy with Autologous Blood Stem Cell Rescue , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[58]  M. Gould,et al.  Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. , 1999, Annals of internal medicine.

[59]  S. Berman,et al.  Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? , 1998, Journal of vascular surgery.

[60]  M. Prins,et al.  Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. , 1998, Current opinion in pulmonary medicine.

[61]  F. Grodstein,et al.  Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. , 1997, American heart journal.

[62]  L. Greenfield,et al.  Clinical Results of Greenfield Filter Use in Patients with Cancer , 1997, Cardiovascular surgery.

[63]  A. Norman,et al.  A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. , 1997, European journal of cancer.

[64]  B. Leduc,et al.  Fibrinolyse des thromboses veineuses profondes sur dispositifs de perfusion implantables. A propos d'une série consécutive de 57 thromboses et de 32 fibrinolyses. , 1996 .

[65]  D. Farge,et al.  Traitement anticoagulant classique de la maladie thromboembolique veineuse chez les patients cancéreux. A propos d'une série rétrospective de 71 patients , 1996 .

[66]  J. Hirsh,et al.  Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. , 1996, The American journal of medicine.

[67]  P. Craft,et al.  Hickman catheters: left-sided insertion, male gender, and obesity are associated with an increased risk of complications. , 1996, Australian and New Zealand journal of medicine.

[68]  R. Rosell,et al.  Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin) , 1996, Thrombosis and Haemostasis.

[69]  M. Burt,et al.  Inferior vena cava filters in cancer patients: indications and outcome. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  M. Prins,et al.  Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. , 1995, Archives of internal medicine.

[71]  J. Renaud-salis,et al.  Methodologie de developpement des standards, options et recommandations diagnostiques et therapeutiques en cancerologie , 1995 .

[72]  B. Eastridge,et al.  Complications of indwelling venous access devices in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Abbruzzese,et al.  The Bird's Nest Filter: An Alternative to Long‐Term Oral Anticoagulation in Patients with Advanced Malignancies , 1994, American journal of clinical oncology.

[74]  J. O'fallon,et al.  Thromboembolism in patients with high-grade glioma. , 1994, Mayo Clinic proceedings.

[75]  L. Deangelis,et al.  Therapy of venous thromboembolism in patients with brain metastases , 1994, Cancer.

[76]  R. Hellman,et al.  Venous Thromboembolism and High Grade Gliomas , 1993, Thrombosis and Haemostasis.

[77]  P. Wen,et al.  Complications of therapy for venous thromboembolic disease in patients with brain tumors , 1993, Neurology.

[78]  S. Rodenhuis,et al.  Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator. , 1993, Thorax.

[79]  M. Citron,et al.  Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer , 1992, Cancer.

[80]  R. Woodruff,et al.  Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. , 1992, Australian and New Zealand journal of medicine.

[81]  J. Ensley,et al.  The Incidence and significance of thromboembolic complications in patients with high‐grade gliomas , 1991, Cancer.

[82]  K. Calligaro,et al.  Thromboembolic complications in patients with advanced cancer: Anticoagulation versus greenfield filter placement , 1991, Annals of vascular surgery.

[83]  M. Citron,et al.  Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. , 1991, Surgery.

[84]  E. Altschuler,et al.  The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. , 1990, Neurosurgery.

[85]  P. Benotti,et al.  Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.

[86]  R. Ruff,et al.  Incidence and treatment of peripheral venous thrombosis in patients with glioma , 1983, Annals of neurology.

[87]  J. Hankinson,et al.  Incidence of lower extremity deep vein thrombosis in neurosurgical patients. , 1980, Neurosurgery.